Teva Pharmaceutical Industries Limited (NASDAQ:TEVA) To Report Earnings

Teva Pharmaceutical Industries Limited (NASDAQ:TEVA) To Report Earnings

Jefferies Group LLC restated a hold rating and issued a $33.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Friday, June 23rd.

Teva also announced a dividend of 8.5 cents, down 75% from Q1's payout. Wells Fargo downgraded the shares of TEVA in report on Monday, January 9 to "Market Perform" rating.

WARNING: "Teva Pharmaceutical Industries Limited's (TEVA) "Hold" Rating Reiterated at Maxim Group" was originally reported by Community Financial News and is the sole property of of Community Financial News. Credit Suisse Group set a $39.00 target price on Teva Pharmaceutical Industries Limited and gave the company a "buy" rating in a research report on Thursday. The rating was downgraded by Mizuho to "Neutral" on Friday, February 10. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) belongs to Healthcare sector, to cut down amount of noise on price chart, shares of firm has 20 days moving average price of -25.98% from last close price of 23.75 and act as support or resistance of price limit. Moreover, Daruma Capital Management Llc has 2.81% invested in the company for 1.04 million shares. Hersha Hospitality Trust has a one bull (extreme weakness) technical rating because it's trading below the 10 day, 50 day and 200 day simple moving averages while the 10-day moving average is below the 50-day moving average and the 50-day moving average is below the 200-day moving average. Teva Pharmaceutical Industries Limited (TEVA) has made its way to a 12-month decline of -55.67%. Stock traders purchased 66,716 put options on the stock. This represents an increase of approximately 864% compared to the typical volume of 6,922 put options. Maxim Group maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) rating on Thursday, March 30.

Teva on Thursday posted second-quarter revenue of $5.69 billion, up 13% year over year, but below the $5.85 billion consensus estimate of analysts. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%.

More news: White House Lays Out Ambitious Deadline For Tax Reform

Specialty revenue dropped 9% during the quarter. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has "Outperform" rating given on Wednesday, November 16 by RBC Capital Markets. If you are accessing this story on another publication, it was copied illegally and reposted in violation of worldwide copyright laws. The correct version of this piece of content can be accessed at

Several institutional investors have recently modified their holdings of the company.

Generics comprise the lion's share of Teva's sales, and will likely become more important as branded drugs like Copaxone face competition. Its pivot point high generated sell signal on Wednesday July 26, 2017, which calls for additional declines until the stock forms a new pivot point low, as this could be a buying opportunity.

Apart from lower prices, Teva said that the company's quarter was hurt by lower volume and the market over-saturation of generic drugs. If we checked the overall image of stock during recent quarter then we found that stock performance is trading down -23.06%. Teva Pharmaceutical Industries Limited's revenue was up 12.9% compared to the same quarter past year. Kistler Tiffany Companies LLC now owns 3,673 shares of the company's stock worth $122,000 after buying an additional 1,571 shares during the period.

Analysts' mean recommendation for Teva Pharmaceutical Industries Limited (TEVA) stands at 2.50. About 67.03M shares traded or 569.63% up from the average. Kistler Tiffany Companies LLC raised its stake in Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. R&D expenses for specialist medicines increased from $235 million in the second quarter of 2016 to $250 million in the second quarter of this year, a 6% increase, mainly due to development expenses for products in the advanced development stages for treatment of fremanezumab and fasinumab.

Related Articles